Adenovirus Vector Vaccine Market

Adenovirus vector vaccine refers to the adenovirus as the carrier, the protective antigen gene is recombinant into the adenovirus genome, using the recombinant adenovirus can express the protective antigen gene made of vaccine.The characteristics of adenovirus vector vaccine showed that the adenovirus vector carrying various antigens can stimulate the body to produce strong humoral immunity or cellular immunity.In addition, since adenovirus vector can infect the respiratory tract and intestinal cells, it can facilitate immunity through the mucosa and induce the body to produce mucosal and systemic immune responses.

Adenovirus Vector Vaccine Market contains market size and forecasts of Adenovirus Vector Vaccine in Global, including the following market information:

• Global Adenovirus Vector Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Adenovirus Vector Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Being Developed Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Adenovirus Vector Vaccine include Johnson & Johnson, CanSino Biologics, Greffex, BravoBio and Altimmune, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Adenovirus Vector Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Adenovirus Vector Vaccine Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Adenovirus Vector Vaccine Market Segment Percentages, by Type, 2021 (%)

• Being Developed
• Preclinical
• Clinical I
• Clinical II

Global Adenovirus Vector Vaccine Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Adenovirus Vector Vaccine Market Segment Percentages, by Application, 2021 (%)

• Pharmaceutical And Biotechnology Companies
• Hospital
• Academic And Research Organizations
• Other

Global Adenovirus Vector Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Adenovirus Vector Vaccine Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Adenovirus Vector Vaccine revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Adenovirus Vector Vaccine revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Johnson & Johnson
• CanSino Biologics
• Greffex
• BravoBio
• Altimmune